Advertisement
Advertisement
URGN
UroGen Pharma Ltd. Ordinary Shares
30.94
USDSponsored
+1.14
+3.83%
May 13, 16:00 UTC -4
Closed
Pre-Market
31.12
+0.18
+0.58%
URGN Earnings Reports
Positive Surprise Ratio
URGN beat 17 of 36 last estimates.
47%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$62.26M
/-$0.29
Implied change from Q1 26 (Revenue/ EPS)
+22.18%
/-38.30%
Implied change from Q2 25 (Revenue/ EPS)
+157.13%
/-72.38%
UroGen Pharma Ltd. Ordinary Shares earnings per share and revenue
On May 06, 2026, URGN reported earnings of -0.47 USD per share (EPS) for Q1 26, beating the estimate of -0.49 USD, resulting in a 4.51% surprise. Revenue reached 50.96 million, compared to an expected 45.72 million, with a 11.47% difference. The market reacted with a +10.16% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -0.29 USD, with revenue projected to reach 62.26 million USD, implying an decrease of -38.30% EPS, and increase of 22.18% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were UroGen Pharma Ltd. Ordinary Shares's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, UroGen Pharma Ltd. Ordinary Shares reported EPS of -$0.47, beating estimates by 4.51%, and revenue of $50.96M, 11.47% above expectations.
How did the market react to UroGen Pharma Ltd. Ordinary Shares's Q1 2026 earnings?
The stock price moved up 10.16%, changed from $23.83 before the earnings release to $26.25 the day after.
When is UroGen Pharma Ltd. Ordinary Shares expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for UroGen Pharma Ltd. Ordinary Shares's next earnings report?
Based on 9
analysts, UroGen Pharma Ltd. Ordinary Shares is expected to report EPS of -$0.29 and revenue of $62.26M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement